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Abstract
Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being 
developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize 
the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing 
the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 
PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned, fully 
sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for 
safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and 
efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated.
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1. Introduction
1.1. Dengue fever: a worldwide public health threat
Dengue fever is caused by infection with dengue viruses, enveloped RNA viruses that occur 
as four recognized serotypes: Dengue type-1, -2, -3, and -4 (DEN-1 to -4) [1]. These viruses 
are transmitted from human to human by mosquitoes (primarily Aedes aegypti) [2]. Infection 
with a dengue virus can cause subclinical disease or overt illness ranging from mild 
symptoms to dengue fever to severe dengue hemorrhagic fever (DHF) [3,4]. Dengue fever is 
characterized clinically as an acute febrile illness with two or more manifestations that can 
include headache, retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, 
or leucopenia [1]. The most severe forms of dengue fever – DHF and dengue shock 
syndrome (DSS) – are life threatening. Dengue is the most rapidly spreading mosquito-
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borne viral disease in the world, and 3.6 billion people in tropical and subtropical areas are 
at risk of dengue infection [5,6]. An estimated 36 million cases of dengue fever occur each 
year, resulting in about 2.1 million cases of DHF/DSS and more than 20,000 deaths, 
primarily among children [5,7].
Infection with one DEN virus serotype results in life-long protection from re-infection by 
that serotype, but does not prevent secondary infection by one of the other three DEN virus 
serotypes [8]. Significantly, previous infection with one DEN serotype may lead to an 
increased risk of severe disease (DHF/DSS) upon secondary infection with a different 
serotype [9]. The specific mechanism causing DHF/DSS is controversial. The pathogenesis 
presented in DHF/DSS patients is thought to result from both viral virulence factors and the 
host immune response [10,11]. It is hypothesized that non-neutralizing antibodies reacting 
with a second DEN strain contribute to viral pathogenesis by antibody-dependent 
enhancement (ADE) of infection [12,13]. Antibody:virus complexes can be directly 
internalized by Fcγ receptor-bearing cells in which dengue virus can replicate, increasing 
virus load (extrinsic ADE). In addition, ligation of Fcγ receptors can inhibit innate immunity 
and increase production of certain cytokines that can increase viral infection and 
pathogenesis (intrinsic ADE) [14].
No dengue vaccine is currently available nor is there an antiviral therapy for dengue virus 
infection. All four dengue serotypes have co-circulated in most endemic countries at various 
times, resulting in concurrent infection by, and protection from, multiple serotypes [15]. 
There have been no reports of sequential disease with a fourth DEN serotype, suggesting 
that effective protection can be obtained by immunization against several serotypes [15,16]. 
Finally, there is the potential for ADE associated with non-neutralizing cross-reactive 
antibodies arising from immunization with monovalent DEN vaccines. Thus, vaccine 
development has focused on tetravalent vaccines that simultaneously provide protection 
against all four serotypes of DEN virus [17].
1.2. Dengue virus vaccines
Tetravalent vaccine candidates in development include mixtures of four different live-
attenuated viruses, recombinant live-attenuated viruses, protein subunit vaccines or DNA 
vaccines [17]. Early efforts at developing a tetravalent vaccine comprising four live-
attenuated viruses developed at Mahidol University were suspended when the DEN-3 
vaccine was found to be insufficiently attenuated [18]. Co-development of live-attenuated 
tetravalent vaccines by the Walter Reed Army Institute of Research and Glaxo-SmithKline 
Biologicals has completed Phase 2 trials [19] but there are currently no plans for additional 
testing.
Three chimeric recombinant dengue vaccines are under active development. Chimeric 
viruses based on a yellow fever virus backbone are in Phase 2b clinical testing in Thailand 
and Phase 3 testing worldwide by Sanofi Pasteur ([20] and reviewed by Guy et al., this 
issue). Recombinant vaccine viruses based on the DEN-2 PDK-53 attenuated virus 
backbone (DENVax) are the subject of this review. Recombinants with a 30 nucleotide 
deletion in the 3′-untranslated region (UTR) of the dengue virus genome were optimized for 
safety and efficacy in preliminary monovalent Phase 1 testing [21]; different tetravalent 
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formulations of these “delta 30” constructs are in Phase 1 clinical testing (reviewed by 
Durbin et al. in this issue).
A recombinant protein vaccine consisting of adjuvanted recombinant envelope (E) proteins 
expressed in insect cells [22] has completed monovalent Phase 1 clinical testing and 
tetravalent formulations have been manufactured (reviewed by Coller et al., this issue). 
Several additional approaches are currently being evaluated in preclinical studies. They 
include the use of (1) adenoviral vectors that express combinations of two of the four dengue 
serotypes [23,24]; (2) DNA vaccines expressing the E protein [25]; and (3) the E protein 
domain III either alone [26], or as domain-based single recombinant envelope protein that 
can induce tetravalent neutralizing antibody responses [27].
1.3. DEN-2 PDK-53: a promising DEN-2 vaccine
The four monovalent DENVax vaccine strains are based on a common DEN virus backbone: 
an attenuated DEN-2 virus strain, termed PDK-53, generated by 53 serial passages in 
primary dog kidney cells [28]. The strain was derived at Mahidol University, Bangkok, 
Thailand from a wild-type DEN-2 virus originally recovered from the serum of a patient 
with DHF/DSS in Thailand (DEN-2 16681). The DEN-2 PDK-53 strain has been 
extensively studied in vitro and in vivo. The strain exhibits an attenuated replication 
phenotype in mammalian and insect cell cultures [28–30], attenuated neurovirulence in 
newborn ICR mice [29,30], and attenuated replication in non-human primates [31]. In 
addition, DEN-2 PDK-53 has been extensively tested in human clinical trials.
1.4. Clinical studies with DEN-2 PDK-53 virus
The DEN-2 PDK-53 strain has been studied clinically both as a monovalent vaccine and in 
multivalent formulations with one or more attenuated dengue virus strains of other 
serotypes. An overview of previous human experience with the DEN-2 PDK-53 strain, 
based on literature reports of completed clinical studies, is provided here (Table 1).
An uncontrolled study of the safety and immunogenicity of DEN-[2 PDK-53 was conducted 
in 10 healthy male Thai volunteers in 1984 [32]. All subjects were non-immune to dengue 
virus; however, five showed evidence of prior exposure to Japanese encephalitis virus. The 
subjects were vaccinated subcutaneously with 4.3–4.4 log10 plaque forming units (PFU) of 
DEN-2 PDK-53 and observed for 21 days post-immunization. No serious adverse reactions 
or abnormal signs (identified as elevated temperature, bleeding, hypotension or organ 
involvement) were observed, and there were no reactions at the injection site. Transient mild 
headache or mild abdominal pain occurring between days 8 and 17 were reported by half of 
the subjects. Other symptoms, including myalgia and eye pain, occurred less frequently. No 
abnormal clinical chemistry findings were observed. Hematology parameters were within 
normal values. There was a slight reduction in total white blood cell counts observed on day 
10 post-immunization that returned to near baseline levels by day 14. All 10 volunteers 
developed neutralizing antibodies to wild-type DEN-2 which persisted for at least 18 
months. Viremia was detected in only one subject on day 10 post-vaccination by 
amplification in cell culture (but not by direct plaque isolation). The isolated virus was 
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identified as DEN-2 and was phenotypically attenuated in vitro. All subjects seroconverted, 
with serum neutralizing antibodies to DEN-2 that persisted for 1.5 years [32].
Vaughn et al. [33] reported on a second Phase 1 study of the safety of the monovalent 
DEN-2 PDK-53 vaccine. A single 3.9–4.3 log10 PFU dose of the DEN-2 PDK-53 vaccine 
was administered subcutaneously in the deltoid region of 10 18–24-year-old American male 
(N = 7) and female (N = 3) volunteers who were non-immune to flavivirus (including 
dengue virus serotypes 1–4, Japanese encephalitis virus, St. Louis encephalitis virus, and 
yellow fever virus). In this uncontrolled study, subjects were observed for 21 days post-
vaccination. Overall, there were no serious adverse reactions reported. There was no 
induration, redness or warmth at the injection site although one subject reported mild arm 
soreness for a few hours after injection. Two subjects did not report any symptoms during 
the observation period. The remaining eight subjects experienced symptoms including 
headache, myalgia and arthralgia, most of which were mild in intensity. One subject 
reported intermittent (5 min to 2 h) headaches on seven days beginning five days after 
vaccination. The headaches resolved without sequelae. Most laboratory results were within 
normal limits. Elevated aspartate amino transferase (AST) levels were observed in two 
patients; both correlated with exercise. As in the Thailand study, a slight reduction in total 
white blood cell counts was observed 8–12 days post-vaccination in seven of the 10 
volunteers. Viremia was detected in eight of the 10 subjects between study days 4 and 12; all 
viruses had small plaque phenotype. All subjects developed neutralizing antibodies that 
persisted for at least one year, and out to two years for the five subjects who were available 
for evaluation at that time point.
1.5. Clinical studies with multivalent formulations containing DEN-2 PDK-53
DEN-2 PDK-53 virus has also been used in combination with up to three live, attenuated 
DEN vaccine strains representing other dengue serotypes, in an attempt to develop a live-
attenuated multivalent vaccine. Bhamarapravati and co-workers [34,35] reported studies in 
healthy adult volunteers in which DEN-2 PDK-53 was evaluated in bivalent combination 
with an attenuated DEN-1 strain (seven volunteers), an attenuated DEN-4 strain (11 
volunteers), in a trivalent mixture with both the DEN-1 and DEN-4 strains (11 volunteers), 
and finally in a tetravalent formulation with attenuated DEN-1, DEN-3 and DEN-4 virus 
strains (six volunteers). The authors state the vaccines were well-tolerated and did not 
produce clinically significant signs, symptoms or laboratory abnormalities [35]. All 
individuals vaccinated with a single dose of the bivalent vaccine formulations demonstrated 
serum neutralizing antibodies against DEN-2 and DEN-1 or DEN-4. Among individuals 
who received a single dose of the tetravalent formulation, five out of six developed DEN-2 
neutralizing antibodies, six out of six developed neutralizing antibodies for DEN-1 and 
DEN-3, and four out of six developed neutralizing antibodies for DEN-4.
On the basis of the promising preliminary data cited above, several clinical trials were 
performed to evaluate and optimize tetravalent vaccine formulations containing DEN-2 
PDK-53 and three other live-attenuated DEN vaccines developed at Mahidol University. 
The attenuated DEN-1, DEN-3 and DEN-4 viruses in these investigational vaccine 
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formulations were derived separately from DEN-2 PDK-53 by serial passage on primary 
dog kidney (PDK) cells or primary African green monkey kidney cells [28].
Kanesathasan et al. [36] described a study of the four monovalent vaccines (N = 5 for each 
group) and the tetravalent formulation (N = 10) compared to a vehicle control (N = 10) in 
adult volunteers. The monovalent vaccines were given in single subcutaneous doses of 3.6–
4.4 log10 PFU and were well-tolerated with few side effects. All vaccinated individuals 
seroconverted to the respective DEN virus. The tetravalent formulation showed significantly 
increased clinical effects compared to the placebo control. The clinical effects were 
associated with high levels of viremia by the DEN-3 vaccine component. Tetravalent 
vaccine recipients seroconverted predominantly to DEN-3 and showed variable 
seroconversion to the other DEN viruses.
Due to the predominance of DEN-3 virus replication, and increased clinical symptoms with 
formulations that included the DEN-3 vaccine, several formulations with higher 
concentrations of the DEN-1, DEN-2 and DEN-4 components and a lower dose of the 
DEN-3 component were tested in adults (N = 59 total for seven formulations [37]) and 
children (N = 40 and N = 42 for each of two different formulations [38]). In these studies, 
the DEN-3 virus was still the dominant replicating vaccine virus and still dominated the 
immune responses. A study with the two preferred formulations was conducted in dengue-
naïve adult volunteers in Australia. Subjects showed significant dengue-like clinical signs 
associated with DEN-3 replication [18] and further studies of this live, attenuated tetravalent 
vaccine were suspended.
Despite the clinical symptoms associated with the attenuated DEN-3 virus component of 
these tetravalent formulations, two follow-up studies of previously vaccinated children 
provided insight into the safety of the DEN-2 PDK-53 component. Using sera from Thai 
children that were given a single dose of the tetravalent vaccine 3–8 years prior, as well as 
samples from naturally infected age-matched controls, Guy et al. [39] studied the ability of 
these sera to stimulate antibody-dependent enhancement (ADE) of viral replication in vitro. 
At low serum dilutions that approximated the concentrations in vivo, assays with sera from 
the vaccinated children resulted either in no ADE or ADE at a similarly low level to that 
observed in naturally infected children. Three of the 16 individuals studied had 
seroconverted only to DEN-2. Two of these sera demonstrated low levels of ADE in vitro at 
levels similar to or much lower than those observed with corresponding age-matched control 
subjects in the endemic area. Within the limits of the in vitro test system used, the vaccinees 
had no apparent increased risk of ADE relative to naturally-infected, age-matched controls.
Chanthavanich et al. [40] reported on the long-term follow-up of 113 Thai children given a 
single dose of the tetravalent vaccine 3–8 years prior, aged 4–15 years at the time of 
vaccination. These children were age- and address-matched with two controls per vaccinee 
in a retrospective study to evaluate the immune response and occurrence of dengue infection 
after vaccination. 75% of the individuals had seroconverted to DEN-2 virus 6–12 months 
post-vaccination while 82% had antibodies to DEN-2 virus 3–8 years (average 6.8 years) 
after vaccination. Similar trends were observed for DEN-1, DEN-3 and DEN-4 viruses. The 
increase in seroconversion is likely due to natural exposure of the children who lived in an 
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endemic area. Importantly, there were no excess hospitalizations for clinically suspected 
dengue fever (DF) or dengue hemorrhagic fever (DHF) in vaccinees (4 of 113, one with DF 
and three with DHF) compared to the unvaccinated control children (14 of 226 with DHF). 
While neither of these studies was sufficiently powered to preclude modest increases in 
severe dengue disease, it is encouraging that immunization with the tetravalent vaccine did 
not cause a high incidence of either ADE in vitro or an increase in the incidence of severe 
dengue illness after long-term follow-up.
1.6. DENVax: chimeric DEN-2 PDK-53-based tetravalent vaccine
As members of the Flavivirus genus of the virus family Flaviviridae, dengue viruses possess 
a single-stranded, positive-sense, approximately 11-kb RNA genome that contains a single 
long open reading frame bracketed by 5′ and 3′ non-coding regions. The gene order in the 
translated polyprotein is capsid–premembrane/membrane (prM/M)–envelope (E)–non-
structural protein 1 (NS1)–NS2A–NS2B–NS3–NS4A–NS4B–NS5 (Fig. 1). Upon cDNA 
cloning and sequence analysis of virus sampled directly from a vial of the Mahidol vaccine, 
two major genetic variants, termed V and E, were identified in the DEN-2 PDK-53 
candidate vaccine virus. Both DEN-2 PDK-53 variants share eight nucleotide mutations, 
relative to the wild-type DEN-2 16681 parent, but the DEN-2 PDK-53-V variant possesses a 
unique ninth mutation in the NS3 gene which modifies the wild-type glutamic acid at 
residue 250 (single letter code, E) to valine (single letter code, V) in the translated NS3 
protein [30].
The DENVax vaccines are based on the genetic background of the DEN-2 PDK-53-V 
variant. The DENVax-2 virus was derived from an infectious cDNA clone of the DEN-2 
PDK-53-V variant. Whole genome sequencing and molecular genetics techniques have 
demonstrated that the mutations that are necessary and sufficient for attenuation of DEN-2 
PDK-53 lie outside the structural genes in the 5′ non-coding region (5′NC), and in non-
structural proteins 1 and 3 (NS1 and NS3) [29]. Attenuated vaccine strains for the DEN-1, -3 
and -4 were engineered by replacing the DEN-2 PDK-53 structural genes, premembrane 
(prM) and envelope (E), with the prM and E genes of wild-type DEN-1, DEN-3 or DEN-4 
virus, as shown in Fig. 1 [41]. The origins of the four wild-type DEN virus strains on which 
the DENVax vaccine is based are shown in Table 2. The chimeric viruses express the 
surface antigens of DEN-1, DEN-3 or DEN-4 and retain six of the nine PDK-53 virus-
specific genetic alterations (mutation in the 5′NC, four amino acid mutations in NS1, NS2A, 
NS3, and NS4A, and a silent mutation at nt 5547), including the three major genetic 
determinants (in the 5′NC, NS1, and NS3) responsible for the attenuation of the DEN-2 
PDK-53 strain (triangles in Fig. 1). Only the DEN-2 PDK-53-V component of DENVax 
retained the PDK-53 virus-specific amino acid mutation in prM and silent mutation at nt 
2055 in the E gene. At the locus of the ninth, silent PDK-53 virus-specific nucleotide 
mutation, the DEN-2 16681 virus-specific C nucleotide was retained in all of the engineered 
vaccine strains. The research grade chimeric DEN viruses have been referred to as 
“ChiDEN-V”. The equivalent viruses, as well as the DEN-2 PDK-53-V virus, re-derived 
under Good Manufacturing Practices (GMP) for vaccine manufacture are referred to as 
“DENVax” (Huang et al., in preparation).
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The ChiDEN-V viruses were shown to retain critical DEN serotype-specific neutralizing 
epitopes using reference neutralizing antibody reagents. In a plaque reduction neutralization 
test, the ChiDEN-V viruses were neutralized to the same extent as the homologous wild-
type DEN virus. The mean plaque size of each of the three ChiDEN-V virus strains was 
significantly smaller than that of the corresponding homologous, wild-type strain in LLC-
MK2 monolayers grown in six-well plates (see fig. 1 in [41]). The ChiDEN-V viruses 
replicated to peak titers of about 6.4–6.9 log10 PFU/mL in LLC-MK2 cells versus the 7.0–
7.6 log10 PFU/mL peak titers of the homologous wild-type DEN viruses (see fig. 1 in [41]). 
The ChiDEN-V viruses also replicated efficiently in Vero cells, with peak titers ranging 
from 6.7 to 7.4 log10 PFU/mL (see fig. 2 in [41]). The ChiDEN-V viruses all exhibited a 
temperature-sensitive phenotype (≥90% reduction in viral titer at 38.7 °C versus 37 °C) in 
LLC-MK2 cells (data not shown; see fig. 1 in [41]).
The ChiDEN-V viruses all exhibited greatly reduced replication profiles and peak 
replication titers when grown in C6/36 (Aedes albopictus mosquito) cells (fig. 2 in [41]). 
The peak titers of these ChiDEN-V viruses were decreased by 3.7–5.8 log10 PFU/mL, 
relative to the peak titers of the wild-type DEN viruses. The common DEN-2 PDK-53 
genetic background shared by these ChiDEN-V viruses clearly controlled their crippled 
replication phenotype in C6/36 cells, as ChiDEN viruses with the wild-type DEN-2 16681 
genetic background exhibited only modest reductions of 0.6–1.8 log10 PFU/mL relative to 
the peak titers of the respective wild-type DEN viruses (see fig. 2 in [41]).
1.7. Genetic stability of DEN-2 PDK-53-based chimeras
The genotype leading to attenuation of the DEN-2 PDK-53 strain has been investigated in 
detail using recombinant viruses with varying combinations of the nine nucleotide 
differences between the DEN-2 PDK-53-V strain and the wild-type parent, 16681. 
Mutations at three loci were found to contribute individually, and synergistically, to PDK-53 
attenuation, specifically, a C to T transition at nucleotide 57 in the 5′ non-coding region 
(5′NC-57), a Gly-to-Asp substitution in non-structural protein 1, amino acid 53 (NS1-53) 
and a Glu-to-Val substitution in non-structural protein 3, amino acid 250 (NS3-250) [29]. It 
is possible that the PDK-53 virus-specific mutations in prM (DEN-2 PDK-53-V virus only), 
NS2A, and/or NS4A might further modulate attenuation to an undefined extent. 
Additionally, the juxtaposition of heterologous genes in the chimeric DEN viruses, 
particularly in ChiDEN-3-V and -4-V, may also contribute to an attenuated phenotype, 
relative to wild-type virus [41].
The genetic stabilities of the ChiDEN-V viruses at the three loci associated with PDK-53 
viral attenuation were evaluated by serial passage of the viral stocks in Vero cell cultures 
(table 2 in [42]). No evidence of reversion at the NS1-53 or NS3-250 locus was observed by 
sequence analyses of the ChiDEN-V viruses at the Vero passage 10. However, the 5′NC-57-
T mutation did show a propensity to revert during passage in Vero cells. A sensitive, 
quantitative single nucleotide polymorphism assay was developed to permit finer assessment 
of the level of reversion at this locus. This TaqMan-based mismatch amplification mutation 
assay (TaqMAMA) permitted detection of less than 1% reversion at the 5′NC-57 locus in 
the viral population [42]. In eight separate ChiDEN-V viral stocks, up to 5% reversion at the 
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5′NC-57 locus was observed at passage level 1. The level of reversion increased with 
passage in all stocks, reaching >50% of the population by passage level 9 in two of the eight 
stocks. This suggests that during passage of the virus in Vero cells, the virus with reversion 
at the 5′NC-57 locus replicates more efficiently than viruses with the attenuating 5′ 
mutation. Refinements in the TaqMAMA currently permit detection of <0.05% reversion at 
the 5′NC-57 locus, and enable the establishment of release criteria to verify an upper limit of 
reversion at this locus in vaccine lots.
Given the propensity of the 5′NC-57 locus to revert, detailed knowledge regarding the 
contribution of each of the three genetic loci of attenuation (individually and in various 
combinations with the other two attenuation loci) to the overall attenuated phenotype of the 
virus is important. Such data have been generated for the DEN-2 PDK-53 virus ([29]; 
summarized in [43]). The NS1-53 attenuation locus (highly stable during passage of the 
ChiDEN-V viruses in Vero cells), when engineered alone in the genetic background of wild-
type DEN-2 16681 virus, encoded nearly complete attenuation of neurovirulence for 
newborn ICR mice, and decreased plaque size in LLC-MK2 cells and decreased replicative 
ability in C6/36 cells to an extent equivalent to that of the single 5′NC-57 attenuating 
mutation engineered in the 16681 background. Only the highly stable NS1-53 and NS3-250 
mutations were identified as genetic loci that significantly contributed to the temperature-
sensitive phenotype of DEN-2 PDK-53 virus [29]. Furthermore, experimental biological 
reversion of any of these indicated phenotypic markers of attenuation to a corresponding 
phenotype approaching that of the wild-type DEN-2 16681 virus required engineered 
reversions in at least two of the three loci, one necessarily at the NS1-53 locus, in the 
PDK-53 genetic background [29]. Thus, in the event of significant reversion at the 5′NC-57 
locus, the current evidence suggests that the partially reverted vaccine virus would retain a 
significantly attenuated phenotype as a result of the remaining, stable attenuating mutations 
at NS1-53 and NS3-250.
2. In vivo properties of DEN-2-PDK-53 chimeric viruses
2.1. Neurovirulence in newborn ICR mice
The neurovirulence of three ChiDEN-V viruses expressing the prM/E genes of DEN 
serotypes 2, 3 and 4 has been examined in newborn ICR mice. Because the wild-type 
DEN-1 16007 strain lacked neurovirulence in newborn ICR mice [44], the ChiDEN-2/1 
virus was not tested for neurovirulence in this model. However, an earlier study 
demonstrated that ChiDEN-2/1 viruses expressing the capsid gene, as well as prM/E genes, 
of DEN-1 16007 virus in the PDK-53 background also lacked neurovirulence for newborn 
ICR mice [44].
The DEN-2 PDK-53 virus and the two ChiDEN-V viruses expressing the prM/E genes of 
DEN serotypes 3 and 4 exhibited attenuation of neurovirulence in groups of newborn ICR 
mice inoculated intracranially with 104 PFU of virus (see Fig. 2, modified from fig. 3 in 
[41]). No mouse mortality, or evidence of illness requiring euthanasia, occurred in mice 
injected with these three viruses. These results contrast with the 87.5%, 100%, and 100% 
morbidity/mortality observed following intracranial challenge with 104 PFU of the 
corresponding wild-type DEN-2 16681, DEN-3 16562 or DEN-4 1036 virus, respectively.
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2.2. Immunogenicity of DEN-2-PDK-53 chimeric viruses in mice
Wild-type DEN-2, DEN-3, and DEN-4 viruses fail to induce robust anti-viral neutralizing 
antibody responses after administration to ICR mice [41,44]. Therefore, the immunogenicity 
of each chimeric virus was tested in transgenic, AG129 knockout mice. This mouse strain 
lacks receptors for interferon-α/β and interferon-γ, and has been shown to be more 
permissive for DEN-2 replication following infection [45]. Immunization of AG129 mice 
with all four serotypes of DEN virus consistently results in production of neutralizing 
antibodies, as measured by neutralization of ≥50% of DEN virus in a plaque-reduction 
neutralization test (PRNT50). Intraperitoneal immunization of adult AG129 mice with 104 
PFU of ChiDEN-2/1-V virus elicited a pooled reciprocal PRNT50 titer of 640 against 
DEN-1 virus, and protected the immunized mice against a severe challenge with the AG129 
mouse-virulent DEN-1 Mochizuki virus (see Table 3, modified from table 5 in [41]). In a 
separate experiment, ChiDEN-2/3V and ChiDEN-2/4-V viruses, each at a dose of 105 PFU, 
elicited neutralizing antibodies in these mice. The magnitude of the neutralizing response in 
the mice immunized with the ChiDEN-2/4-V virus (pooled reciprocal primary and boosted 
titers of 40 and 320, respectively) was less robust than in mice that received ChiDEN-3-V 
(160 and 640, respectively) (Table 3, modified from table 6 in [41]).
A tetravalent formulation of the ChiDEN-V viruses, containing 105 PFU of each virus, 
elicited high neutralizing antibody titers against wild-type DEN-1 (pooled reciprocal 
primary and boosted titers of 640 and 2560, respectively), DEN-2 (1280 and 2560), DEN-3 
(160 and 1280), and DEN-4 (80 and 320) viruses in adult AG129 mice (Table 4; see table 7 
in [41]). The neutralizing antibody titers were similar to the homologous titers elicited by 
each monovalent virus, indicating no significant interference among the vaccine components 
in tetravalent formulations in the AG129 mouse model.
2.3. Preparation for clinical trials: a summary of preclinical development of DENVax
The extensive clinical data with DEN-2 PDK-53 and the in vitro and in vivo preclinical 
characterization of the DEN-2 PDK-53-based recombinant chimeras reviewed above support 
the testing of tetravalent DENVax formulations in human clinical trials. To complete 
preclinical development of the DENVax vaccine, manufacturing quality DENVax strains 
were derived by transfection of clinical grade Vero cells with RNA transcribed from cDNA 
clones of each of the four DENVax viruses. These strains were plaque purified and 
expanded to make the master seed viruses, working seed viruses and bulk vaccine 
preparations. The master seed strains were completely sequenced and characterized in vitro 
and in vivo to verify retention of all attenuation markers (Huang, et al., in preparation). 
Tetravalent formulations were manufactured by combining the bulk vaccines with excipients 
that promote the thermal stability of dengue viruses (Wiggan et al., submitted). Tetravalent 
DENVax formulations were tested in preclinical models for safety (Huang et al., in 
preparation). The DENVax formulations also were tested for efficacy in non-human 
primates [46].
2.4. Safety, immunogenicity and efficacy of tetravalent DENVax vaccines in monkeys
Monkeys infected with DEN virus do not develop clinical symptoms. However, viremia and 
the development of DEN virus-specific neutralizing antibodies have been regarded as 
Osorio et al. Page 9













markers of safety and immunogenicity for candidate DEN vaccines. Early immunogenicity 
studies in monkeys with the ChiDEN-V viruses were conducted at Mahidol University [47]. 
More recently, we evaluated the safety and efficacy of three tetravalent formulations 
containing different ratios of DENVax viruses in cynomolgus macaques (Macaca 
fascicularis) [46]. A formulation termed 3:3:3:3 contained 103 PFU per dose of each of the 
four DENVax viruses. The 3:3:5:5 formulation contained 103 PFU of DENVax-1 and 
DENVax-2 and 105 PFU of DENVax-3 and DENVax-4 per dose. A 5:5:5:5 formulation 
contained 105 PFU of each of the four viruses. Subcutaneous injection of the three DENVax 
formulations was well-tolerated. Transient, low level viremia of only the DENVax-2 
component was detected after the primary immunization (≤2.4 log PFU/mL for no more 
than five consecutive days), yet virus neutralizing antibody titers were induced against all 
four dengue virus serotypes after one or two administrations of vaccine (see Fig. 3, from 
table 1 in [46]). Significant neutralizing antibody titers were induced to DEN-1, DEN-2 and 
DEN-3 by one or two administrations of the tetravalent formulations. The neutralizing 
antibody responses to DEN-4 were significantly lower. The 3:3:5:5 formulation, containing 
increased titers of DENVax-3 and DENVax-4, provided the most balanced neutralizing 
antibody responses. Many animals seroconverted to multiple DEN serotypes (as defined as a 
PRNT50 titer of >10 and a four-fold increase over pre-immunization titer). Significant 
seroconversion to each DEN serotype (greater than 87.5% seroconversion) was observed 
after two immunizations with either the 3:3:5:5 or 5:5:5:5 formulation (Table 5). After 
immunization, animals were segregated into four cohorts for challenge with each of the four 
wild-type DEN serotypes. While non-human primates do not show clinical signs after DEN 
infection, there is demonstrable viremia. All animals immunized with the high dose 
formulation (5:5:5:5) were protected from viremia after challenge with each of the four 
DENV. Immunization with the lower dose formulations (3:3:3:3 and 3:3:5:5) completely 
protected animals from viremia caused by DEN-3 virus or DEN-4 virus; immunized animals 
were partially protected from viremia caused by DEN-1 and DEN-2. These data guided the 
choice of tetravalent DENVax formulations to be used in subsequent human clinical trials.
The manufacturing and characterization of the DENVax vaccines and data from the 
preclinical safety, immunogenicity and efficacy studies were submitted to the Food and 
Drug Administration (FDA) as an Investigational New Drug application (IND). In addition, 
the data were submitted to the Instituto Nacional de Vigilancia de Medicamentos y 
Alimentos (INVIMA) the regulatory authorities in Colombia, in support of Phase 1 clinical 
trials.
2.5. Initial Phase 1 study in healthy U.S. volunteers
The first clinical trial to investigate the safety and preliminary immunogenicity of the 
tetravalent DENVax vaccine is being conducted in healthy adult volunteers in the United 
States and is sponsored by the Division of Microbiology and Infectious Disease (DMID) of 
the National Institute of Allergy and Infectious Disease (NIAID). DMID is conducting the 
clinical trial at its Vaccine and Treatment Evaluation Unit (VTEU) at St. Louis University, 
St. Louis, MO (see www.clinicaltrials.gov). The primary objective of the DMID-sponsored 
study is to assess the safety and tolerability of the vaccine following administration of two 
doses of vaccine on days 0 and 90. The study is enrolling a total of 72 subjects, randomized 
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to one of four groups. Subjects within each group are randomized to receive vaccine or 
placebo (Phosphate Buffered Saline; PBS) in a 12:6 ratio. The first two groups receive a low 
dose formulation of DENVax (approximately 104 PFU of DENVax-1, 103 PFU of 
DENVax-2, 104 PFU of DENVax-3 and 105 PFU of DENVax-4) (or placebo) administered 
by either subcutaneous (SC) or intradermal (ID) injection in the deltoid region. The 
subsequent two groups are receiving a high dose formulation of DENVax (approximately 
105 PFU of DENVax-1, 104 PFU of DENVax-2, 105 PFU of DENVax-3 and 105 PFU of 
DENVax-4 per dose) or placebo, again administered by either SC or ID injection in the 
deltoid region. Subjects are vaccinated on day 0 and boosted with the same dose on day 90. 
Primary outcome measures include the incidence and severity of vaccine-associated Adverse 
Events (AEs) from the time of the first dose of vaccine through the end of the study, as well 
as an assessment of vaccine reactogenicity based on the incidence and severity of solicited 
AEs recorded during the first 14 days after each dose administration. The secondary 
objective of the study is to evaluate the immune response to the vaccine based on the levels 
of neutralizing antibodies to each of the four dengue serotypes and the proportion of subjects 
who seroconvert to each of the four dengue serotypes. The level of viremia associated with 
each vaccine virus serotype is being assessed based on the quantity of viral RNA in the 
blood.
2.6. Ongoing Phase 1 study in a dengue non-endemic region of Colombia
To assess the safety and efficacy of the vaccine in a population reflective of those at most 
risk of disease, a second Phase 1 study is being conducted in healthy, flavivirus-naïve, adult 
volunteers in a high altitude region of Colombia. At high altitude, there is no Aedes aegypti 
and no endemic dengue disease. The objectives of this Inviragen-sponsored study are to 
evaluate the safety, tolerability and immunogenicity of the DENVax vaccine in healthy 
adults following subcutaneous or intradermal administration at two different dose levels 
compared to a saline placebo. The study is evaluating the same dose levels and dosing 
schedule as the DMID-sponsored study being conducted in the United States, but will enroll 
a larger number of subjects per group from a population more representative of those in 
most need of the vaccine.
3. Discussion
There are numerous advantages to a tetravalent, chimeric dengue vaccine based on the well-
characterized DEN-2 PDK-53 backbone. The mutations in the viral non-structural genes 
which are necessary and sufficient to express the attenuated phenotype of DEN-2 PDK-53 
have been genetically identified [29,41]. The three recombinant virus strains for DEN-1, 
DEN-3, and DEN-4 contain the same attenuating mutations as the parental DEN-2 PDK-53 
strain. Since all four DENVax components share the identical attenuating mutations, 
recombination between vaccine strains cannot generate more pathogenic viruses.
Direct knowledge of the attenuating mutations in these vaccine candidates permits the 
design of specific genetic quality control tests to ensure that the vaccine used in clinical 
studies maintains the attenuated genotype. We have sequenced the genomes of the master 
seed DENVax viruses to assure the presence of the attenuating mutations in the 5′NCR, 
NS-1 and NS-3. In addition, we use spot-sequencing of the attenuation loci as a release test 
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for GMP preparations of each of the four DENVax viruses. The presence of the attenuating 
mutations assures that the vaccine viruses do not replicate as efficiently as wild-type dengue 
viruses in mammalian and mosquito cells [41]. Animal model testing demonstrates that the 
pathogenicity of the vaccine viruses is significantly attenuated compared to wild-type 
dengue viruses [41].
Attenuation of the viruses through the three mutations in the DEN-2 PDK-53 backbone is 
achieved without compromising the ability of each of the four viruses to elicit an appropriate 
serotype-specific neutralizing antibody response. The individual monovalent vaccines and 
mixtures of all four DENVax viruses induce neutralizing antibody responses to all four DEN 
viruses in mice [41] and in monkeys [46]. Although there currently is no DEN-3 or DEN-4 
challenge model in adult mice, AG-129 mice immunized with tetravalent DENVax 
formulations are protected from infection by wild-type DEN-1 or DEN-2 viruses ([41]and 
Huang et al., in preparation). Monkeys immunized with tetravalent DENVax formulations 
are protected from challenge with wild-type DEN-1, DEN-2, DEN-3 or DEN-4 virus [46]. 
In this study, animals were challenged 30 days post second vaccination and the short 
timeframe from vaccination to challenge would be considered by some to not be optimal 
when testing vaccine protective efficacy.
Mice or monkeys immunized with a priming dose of tetravalent DENVax show no, or 
significantly reduced, viremia and no signs of disease when a second dose of DENVax is 
administered. Similarly, monkeys immunized with two doses of DENVax show no signs of 
disease and no, or low, viremia upon subsequent challenge with wild-type DEN viruses [46]. 
Thus, DENVax administration does not enhance the infectivity of subsequent doses of live-
attenuated or wild-type dengue viruses.
Phase 1 studies of the monovalent DEN-2 PDK-53 candidate vaccine showed that the strain 
is safe, well-tolerated and generates long-lasting neutralizing antibody and cell-mediated 
immune responses to DEN-2 [32,33,40]. Vaccination of healthy adult subjects and children 
with the live-attenuated DEN-2 PDK-53 virus has been well tolerated and immunogenic in 
both monovalent and multivalent vaccine formulations. The vaccine development studies 
described in this review have culminated in the testing of tetravalent DENVax formulations 
in human clinical trials. The Phase 1 studies in progress at the time of this review are 
designed to determine if DENVax is safe in healthy adults who are flavivirus negative. The 
safety profile of DENVax is being determined not only in U.S. adults but also in adults in 
Colombia, in a high altitude, non-endemic region. In addition, preliminary immunogenicity 
results from these trials will assess whether two different formulations of DENVax can elicit 
neutralizing antibodies to all four dengue vaccines. Finally, DENVax is being delivered by 
two different routes of administration (SC and ID) in these early Phase 1 studies.
The DENVax vaccine is considerably different from previously tested tetravalent vaccines 
in that all four strains contain the same attenuating mutations as the DEN-2 PDK-53 strain, a 
strain that has been shown to be both safe and immunogenic in humans. Clinical data from 
the ongoing studies will shed light on whether these advantages translate to a safe dengue 
vaccine that can rapidly induce neutralizing antibodies against all four DEN serotypes. Such 
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a vaccine is critically needed to protect people from the threat of dengue infection and 
improve public health worldwide.
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Genetic structure of DENVax vaccine strains. The diagram shows the gene arrangements for 
the parental DEN-2 PDK-53 as well as the three chimeras, DENVax-1, -3 and -4. Arrows 
indicate the three pivotal mutations in DEN-2 PDK-53 that determine the attenuating 
phenotype of the viruses (see text). Shading indicates the origin of the prM and E genes in 
the chimeras.
See Huang et al. [41] for details.
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Neurovirulence of ChiDEN-V viruses in newborn ICR mice. Newborn ICR mice were 
challenged intracranially with 104 PFU of each virus. Percent mortality = dead mice and 
mice euthanized at signs of morbidity.
Data are from fig. 2 in Huang et al. [41].
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Neutralizing antibody titers after DENVax administration to non-human primates. Groups of 
eight cynomolgus macaques were immunized with the three indicated tetravalent DENVax 
formulations (see text) on days 0 and 60. Sera were collected at various time points after 
immunization. The figure indicates geometric mean PRNT50 30 days after the primary 
(“Prime”) and 30 days after the secondary (“Boost”) immunizations for each of the four 
DEN serotypes.
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Table 1
Summary of literature pertaining to human clinical experience with DEN-2 PDK-53.
Author (year of 
publication) [reference] Study design Observations
Bhamarapravati (1987) [32] Single subcutaneous (SC) dose of 
monovalent DEN-2 PDK-53 to 10 healthy 
adult dengue negative volunteers.
Safety: No reactions at the injection site. Headache and 
abdominal pain reported in 5 of 10 subjects. Myalgia, anorexia 
and nausea occurred less frequently. Viremia: Detected in one 
volunteer on day 10. Immunogenicity: Seroconversion in all 
subjects to DEN-2 that persisted for 1.5 years
Vaughn (1996) [33] Single SC dose of monovalent DEN-2 
PDK-53 to 10 healthy adult dengue 
negative volunteers.
Safety: No reactions at the injection site. Transient headache, 
myalgia and arthralgia reported in several subjects. Viremia: 
Detected in 8 of 10 subjects between days 4 and 12. 
Immunogenicity: Seroconversion to DEN-2 detected in all 
subjects. Neutralizing antibody response persisted.
Bhamarapravati (2000) [35] Single SC dose of bivalent DEN-2 PDK-53 
with DEN-4 or DEN-1 or trivalent with 
DEN-1 and DEN-4. Single SC dose of 
tetravalent formulation.
Safety: No details of observed side effects; authors stated that 
the vaccines were well-tolerated. Viremia: No data provided. 
Immunogenicity: Seroconversion in all subjects to two or three 
serotypes given bivalent or trivalent vaccines, respectively. All 
six subjects given tetravalent vaccine seroconverted to DEN-1 
and DEN-3, five of six converted to DEN-2 and four of six 
seroconverted to DEN-4.
Kanesathasan (2001) [36] Single SC dose of monovalent DEN-2 
PDK-53 to five healthy flavivirus 
seronegative adult volunteers.
Safety: No reactions at the injection site. Mild symptoms of 
headache (4), myalgia, malaise, pruritus or transient fever 
reported. Slight leukopenia in two subjects around day 10. 
Viremia: Virus isolation by polymerase chain reaction (PCR) in 
20% of subjects days 7–10 post dosing. Immunogenicity: All 
seroconverted.
Kanesathasan (2001) [36] Single SC dose of tetravalent vaccine: 
DEN-2 PDK-53 combined with live-
attenuated DEN-1, DEN-3 and DEN-4a, to 
10 healthy adult volunteers.
Safety: Erythema at the injection site in 2 of 10 volunteers. 
Moderate headache, malaise and myalgia, eye pain and pruritus 
were common. Four subjects had mild fever and all experienced 
maculopapular rashes over the trunk and extremities. Increased 
liver enzymes in a majority of subjects. Viremia: Detected in all 
subjects between days 5 and 12, identified as DEN-3. One 
volunteer had concurrent DEN-3 and DEN-4 viremia on day 11. 
Immunogenicity: Highest antibody titers were to DEN-3 but 
only one subject seroconverted to all four DEN serotypes.
Sabchareon (2002) [37] Two doses of tetravalent vaccine given 6 
months apart to 59 adults. Dosed with 
placebo (N = 10) or various tetravalent 
formulationsa combinations of dose. 
Safety: Majority of subjects with mild to 
headache, rash, eye pain, fever and 
myalgia. Five subjects were hospitalized 
for dengue-like fever with concomitant 
severe neutropenia and thrombocytopenia. 
Best safety profile observed in groups with 
lowest dose of DEN-3 (1 log10 PFU) 
suggesting the DEN-3 virus was associated 
with adverse events. Viremia: DEN-3 virus 
detected in 47 of 49 subjects after first 
dose. DEN-2 or DEN-4 viremia detected in 
21 of 47 after second dose. 
Immunogenicity: 100% seroconversion to 
DEN-3, 85%, 78% and 71% 
seroconversion to DEN-1, DEN-2 and 
DEN-4 after the second dose
Sabchareon (2004) [38] Three doses of tetravalent vaccinea; 0, 3–5 
months and 8–12 months. Subjects were 
103 healthy children aged 5–12 years. Two 
tetravalent formulations tested.
Safety: After first dose, mild to moderate symptoms fever, rash, 
headache and myalgia observed in 79%–90% of subjects. Five 
subjects had severe reactions including dengue-like fever in one 
subject. Mild and moderate increases in ALT and neutropenia 
observed after first dose. Viremia: DEN-3 viremia observed in 
>75% of subjects after first dose but not seen thereafter. Viremia 
for DEN-1, DEN-2 and DEN-4 seen after first, second and third 
doses in a small percentage of subjects. Immunogenicity: 100% 
seroconversion for DEN-1, DEN-2 and DEN-3; 89–100% 
seroconversion to DEN-4 after three doses.
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Author (year of 
publication) [reference] Study design Observations
Kitchener (2006) [18] One dose of two formulations of 
tetravalent vaccinea administered adult 
volunteers. All subjects seronegative for 
dengue.
Safety: All 10 subjects developed mild to moderate reactions 
consistent with mild dengue-like syndrome, including fever, 
headache, malaise, nausea or vomiting, arthralgia, myalgia, eye 
pain and skin rash. Study was discontinued by the sponsor prior 
to administration of intended second dose. Viremia: DEN-3 
detected in seven of 10 subjects. DEN-4 was detected in two 
subjects. DEN-1 and DEN-2 were not detected. Immunogenicity: 
Seroconversion in all subjects to DEN-3. Six of 10 
seroconverted to DEN-1 and DEN-4 and four of 10 
seroconverted to DEN-2.
Chanthavanich (2006) [40] Single dose of various formulations of 
tetravalent vaccinea administered to 113 
volunteers aged 4–15 years. Age and 
address matched with 226 controls. 
Follow-up 3–8 years after vaccination.
Safety: No excess hospitalizations for clinically suspected 
dengue fever or DHF in vaccinees (4 of 113: one with dengue 
fever and three with hemorrhagic fever) compared to the 
unvaccinated control children (14 of 226 with dengue 
hemorrhagic fever). Immunogenicity: 75% of the individuals had 
seroconverted to DEN-2 virus 6–12 months post-vaccination 
while 82% had seroconverted 3–8 years after vaccination. 
Similar trends were observed for DEN-1, DEN-3 and DEN-4. 
The increase in seroconversion is likely due to natural exposure 
of the children in the endemic area.
a
Attenuated DEN-1, DEN-3 and DEN-4 strains in the tetravalent vaccines were independently derived by serial passage in cell culture and were 
not based on DEN-2 PDK-53.
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Table 2
Sources of prM/E gene regions in DENVax vaccine viruses.
Virus Strain Origin Source Reference
Viral origins of the prM/E gene region expressed in ChiDEN and DENVax vaccine virusesa
DEN-1 16007 Thailand, 1964 DHF/DSS patient Halstead and Simasthien [48]
DEN-2 16681 Thailand, 1964 DHF/DSS patient Halstead and Simasthien [48]
DEN-3 16562 Philippines, 1964 DHF patient Halstead and Simasthien [48]
DEN-4 1036 Indonesia, 1976 DF patient Gubler et al. [49]
a
See table 1 in [43].




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Vaccine. Author manuscript; available in PMC 2015 October 02.
